Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: A Hungarian analysis

European Journal of Health Economics

Volumn 8, Issue 2, 2007, Pages 161-168

  Palmer, Andrew J ^a   Valentine, William J ^a   Ray, Joshua A ^a   Roze, Stephane ^a   Muszbek, Noemi ^b  

^a IQVIA   (United States)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Costs; Hungary; Irbesartan; Microalbuminuria; Modeling; Nephropathy

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; IRBESARTAN; PERIPHERAL VASODILATING AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; HUNGARY; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; LIFE EXPECTANCY; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY;

ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; COHORT STUDIES; COMORBIDITY; COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HUNGARY; HYPERTENSION; KIDNEY FAILURE, CHRONIC; LIFE EXPECTANCY; MARKOV CHAINS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); TETRAZOLES;

EID: 34248326909     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-006-0033-2     Document Type: Article

References (22)

1. Ritz, E., Rychlik, I., Locatelli, F., Halimi, S.: End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am. J. Kidney. Dis. 34(5), 795-808 (1999)
2. Adeghate, E., Schattner, P., Peter, A., Dunn, E., Donath, T.: Diabetes mellitus and its complications in a Hungarian population. Arch. Physiol. Biochem. 109(3), 281-291 (2001)
3. Molnar, M., Wittmann, I., Nagy, J.: Prevalence, course and risk factors of diabetic nephropathy in type-2 diabetes mellitus. Med. Sci. Monit. 6(5), 929-936 (2000)
4. Parving, H.H., Lehnert, H., Brochner-Mortensen, J., Gomis, R., Andersen, S., Arner, P.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 345(12), 910-912 (2001)
5. Lewis, E.J., Hunsicker, L.G., Clarke, W.R., Berl, T., Pohl, M.A., Lewis, J.B., et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345(12), 851-860 (2001)
6. Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H.H., et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345(12), 861-869 (2001)
7. Palmer, A.J., Annemans, L., Roze, S., Lamotte, M., Lapuerta, P., Chen, R., et al.: Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 27(8), 1897-1903 (2004)
8. Gaede, P., Vedel, P., Larsen, N., Jensen, G.V., Parving, H.H., Pedersen, O.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348(5), 383-393 (2003)
9. World Health Organization. Life tables for 191 countries. World mortality in 2000. http://www.3.who.int/whosis/life_tables/life_tables.cfm?path=evidence, life_tables&language=english (2002)
10. Stehouwer, C.D., Gall, M.A., Twisk, J.W., Knudsen, E., Emeis, J.J., Parving, H.H.: Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51(4), 1157-1165 (2002)
11. Briggs, A.H.: Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17(5), 479-500 (2000)
12. Járay, J., Kaló Z., Nagy, J.: Dialízis versus-vesetranszplantáció összehasonlító költséghatékonysági elemzé s, Klinikai kiválóság. Springer, Heidelberg (1999)
13. Adler, A.I., Stevens, R.J., Manley, S.E., Bilous, R.W., Cull, C.A., Holman, R.R.: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 63(1), 225-232 (2003)
14. Rodby, R.A., Chiou, C.F., Borenstein, J., Smitten, A., Sengupta, N., Palmer, A.J., et al.: The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin. Ther. 25(7), 2103-2119 (2003)
15. Lacourciere, Y., Nadeau, A., Poirier, L., Tancrede, G.: Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension 21(6 Pt 1), 786-794 (1993)
16. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V., et al.: Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int. Suppl. 45, S150-S155 (1994)
17. Trevisan, R., Tiengo, A.: Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am. J. Hypertens 8(9), 876-883 (1995)
18. Agardh, C.D., Garcia-Puig, J., Charbonnel, B., Angelkort, B., Barnett, A.H.: Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J. Hum. Hypertens 10(3), 185-192 (1996)
19. Tatti, P., Pahor, M., Byington, R.P., Di Mauro, P., Guarisco, R., Strollo, G., et al.: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21( 4), 597-603 (1998)
20. Gaede, P., Vedel, P., Parving, H.H., Pedersen, O.: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomiised study. Lancet 353, 617-622 (1999)
21. Chan, J.C., Ko, G.T., Leung, D.H., Cheung, R.C., Cheung, M.Y., So, W.Y., et al.: Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int. 57(2), 590-600 (2000)
22. Estacio, R.O., Jeffers, B.W., Gifford, N., Schrier, R.W.: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23(Suppl 2), B54-B64 (2000)